Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Curr Top Med Chem ; 23(7): 520-538, 2023.
Article in English | MEDLINE | ID: covidwho-20243928

ABSTRACT

Viral infections range from self-limiting to more serious and fatal infections; therefore, some viral infections are of great public health concern worldwide, e.g., Hepatitis B virus, Hepatitis C virus, and HIV. Recently, the world faced a new infection due to the coronavirus, COVID-19, which was announced as a pandemic in early 2020. This virus infected more than 500 million people, killing around 6 million people worldwide. On the other hand, the increase in drug-resistant strains is also creating serious health problems. Thus, developing new selective antiviral agents with a different mode of action to fight against mutated and novel viruses is a primary goal of many researchers. Taking into account the role of heterocyclic compounds in drug discovery as a key structural component of most of the bioactive molecules; herein, we report an extensive review of the antiviral activity of five-membered heterocyclic compounds reported from 2015 to date. In this review, the antiviral activities of the agents containing the specified ring systems thiadiazoles, triazoles, oxadiazoles, and thiazoles are discussed.


Subject(s)
COVID-19 , Heterocyclic Compounds , Thiadiazoles , Virus Diseases , Humans , Antiviral Agents/chemistry , Virus Diseases/drug therapy , Heterocyclic Compounds/pharmacology , Heterocyclic Compounds/therapeutic use , Thiadiazoles/chemistry
2.
Med Chem ; 19(8): 717-729, 2023.
Article in English | MEDLINE | ID: covidwho-2257282

ABSTRACT

Severe emergencies occurred across the globe, beginning with the outbreak of SARSCoV in 2002, followed by MERS-CoV in 2012. In December 2019, an acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China as the agent responsible for the recent COVID-19 pandemic outbreak. The virus rapidly spread throughout the world due to its high transmissibility, leading to enormous health problems and complexities. The COVID-19 pandemic has affected public health, the weak persons were severely affected by this virus. To stop the disease from spreading further, effective remedies are the need of the hour. Although SARS-CoV-2 vaccination campaigns are being carried out all over the globe, several new SARS-CoV-2 variants have emerged, and each has caused a wave of infections, highlighting an urgent need for therapeutics targeting SARS-CoV-2. Heterocyclic compounds have been explored extensively for a very long time for their biological activities, namely, anti-inflammatory, antimalarial, antitubercular, anticancer, antiviral, antimicrobial, antidiabetic, and many more bio-activities. Through this review, the author has tried to report the heterocyclic compounds synthesized all over the world over the last 2 years to fight against the SARS CoV-2 coronaviruses. The heterocyclic motifs mentioned in the review can serve as important resources for the development of COVID-19 treatment methods.


Subject(s)
COVID-19 , Heterocyclic Compounds , Humans , COVID-19/epidemiology , SARS-CoV-2 , Pandemics , COVID-19 Drug Treatment , COVID-19 Vaccines , Heterocyclic Compounds/pharmacology , Heterocyclic Compounds/therapeutic use
3.
Molecules ; 27(16)2022 Aug 19.
Article in English | MEDLINE | ID: covidwho-1997716

ABSTRACT

In addition to vaccines, antiviral drugs are essential in order to suppress COVID-19. Although some inhibitor candidates have been determined to target the SARS-CoV-2 protein, there is still an urgent need to continue researching novel inhibitors of the SARS-CoV-2 main protease 'Omicron P132H', a protein that has recently been discovered. In the present study, in the search for therapeutic alternatives to treat COVID-19 and its recent variants, we conducted a structure-based virtual screening using docking studies for a new series of pyrazolo[3,4-d]pyrimidin-4(5H)-one derivatives 5-13, which were synthesized from the condensation reaction of pyrazolopyrimidinone-hydrazide (4) with a series of electrophiles. Some significant ADMET predictions-in addition to the docking results-were obtained based on the types of interactions formed and the binding energy values were compared to the reference anti- SARS-CoV-2 redocked drug nirmatrelvir.


Subject(s)
COVID-19 Drug Treatment , Heterocyclic Compounds , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Heterocyclic Compounds/pharmacology , Humans , Molecular Docking Simulation , Molecular Dynamics Simulation , Protease Inhibitors/chemistry , SARS-CoV-2
4.
Clin Lymphoma Myeloma Leuk ; 22(8): e716-e729, 2022 08.
Article in English | MEDLINE | ID: covidwho-1763647

ABSTRACT

INTRODUCTION: Induction therapy for multiple myeloma is traditionally capped at 6 cycles of lenalidomide due to concerns that longer treatment compromises the ability to collect sufficient stem cells for autologous stem cell transplantation (ASCT). However, during the COVID-19 pandemic, many of our patients received prolonged lenalidomide induction due to concerns about proceeding to ASCT. We investigated whether prolonged induction with lenalidomide affects the efficacy of stem cell collection among patients mobilized with cyclophosphamide and/or plerixafor. PATIENTS AND METHODS: This single center, retrospective study included patients who were treated with lenalidomide induction regimens, received mobilization with cyclophosphamide or plerixafor, and underwent apheresis in preparation for ASCT. 94 patients were included, 40 of whom received prolonged induction with >6 cycles of lenalidomide containing regimen. RESULTS: Patients who received prolonged induction were more likely to require >1 day of apheresis (38% vs. 15%; OR 3.45; P = .0154), and there was a significant correlation between the duration of lenalidomide treatment and the apheresis time required to collect sufficient cells for transplant (R2 = 0.06423, P = .0148). However, there was no significant difference between patients who received prolonged induction and those who did not with respect to CD34+ stem cell yields at completion of apheresis (9.99 vs. 10.46 cells/Kg, P = .5513) or on the first day of collection (8.29 vs. 9.59 cells/Kg, P = .1788). CONCLUSION: Among patients treated with >6 cycles of lenalidomide, mobilization augmented with cyclophosphamide and/or plerixafor will likely facilitate sufficient stem cell harvest to permit ASCT.


Subject(s)
Hematopoietic Stem Cell Transplantation , Heterocyclic Compounds , Lenalidomide , Multiple Myeloma , Benzylamines/therapeutic use , COVID-19 , Cyclams/therapeutic use , Cyclophosphamide/therapeutic use , Hematopoietic Stem Cell Mobilization/methods , Heterocyclic Compounds/pharmacology , Heterocyclic Compounds/therapeutic use , Humans , Lenalidomide/therapeutic use , Multiple Myeloma/drug therapy , Pandemics , Retrospective Studies , Transplantation, Autologous
5.
Brief Bioinform ; 22(2): 1476-1498, 2021 03 22.
Article in English | MEDLINE | ID: covidwho-1352121

ABSTRACT

Coronavirus disease 2019 (COVID-19), an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a global pandemic by the World Health Organization, and the situation worsens daily, associated with acute increases in case fatality rates. The main protease (Mpro) enzyme produced by SARS-CoV-2 was recently demonstrated to be responsible for not only viral reproduction but also impeding host immune responses. The element selenium (Se) plays a vital role in immune functions, both directly and indirectly. Thus, we hypothesised that Se-containing heterocyclic compounds might curb the activity of SARS-CoV-2 Mpro. We performed a molecular docking analysis and found that several of the selected selenocompounds showed potential binding affinities for SARS-CoV-2 Mpro, especially ethaselen (49), which exhibited a docking score of -6.7 kcal/mol compared with the -6.5 kcal/mol score for GC376 (positive control). Drug-likeness calculations suggested that these compounds are biologically active and possess the characteristics of ideal drug candidates. Based on the binding affinity and drug-likeness results, we selected the 16 most effective selenocompounds as potential anti-COVID-19 drug candidates. We also validated the structural integrity and stability of the drug candidate through molecular dynamics simulation. Using further in vitro and in vivo experiments, we believe that the targeted compound identified in this study (ethaselen) could pave the way for the development of prospective drugs to combat SARS-CoV-2 infections and trigger specific host immune responses.


Subject(s)
Antiviral Agents/pharmacology , Coronavirus 3C Proteases/antagonists & inhibitors , Heterocyclic Compounds/pharmacology , Protease Inhibitors/pharmacology , Selenium/analysis , Antiviral Agents/chemistry , Computational Biology , Computer Simulation , Coronavirus 3C Proteases/chemistry , Heterocyclic Compounds/chemistry , Humans , Ligands , Models, Molecular , Molecular Docking Simulation , Molecular Dynamics Simulation , Protease Inhibitors/chemistry , Protein Structure, Tertiary , Pyrrolidines/chemistry , Pyrrolidines/pharmacology , Reproducibility of Results , Sulfonic Acids
6.
Int J Mol Sci ; 22(15)2021 Aug 03.
Article in English | MEDLINE | ID: covidwho-1346502

ABSTRACT

Thrombosis is a life-threatening disease with a high mortality rate in many countries. Even though anti-thrombotic drugs are available, their serious side effects compel the search for safer drugs. In search of a safer anti-thrombotic drug, Quantitative Structure-Activity Relationship (QSAR) could be useful to identify crucial pharmacophoric features. The present work is based on a larger data set comprising 1121 diverse compounds to develop a QSAR model having a balance of acceptable predictive ability (Predictive QSAR) and mechanistic interpretation (Mechanistic QSAR). The developed six parametric model fulfils the recommended values for internal and external validation along with Y-randomization parameters such as R2tr = 0.831, Q2LMO = 0.828, R2ex = 0.783. The present analysis reveals that anti-thrombotic activity is found to be correlated with concealed structural traits such as positively charged ring carbon atoms, specific combination of aromatic Nitrogen and sp2-hybridized carbon atoms, etc. Thus, the model captured reported as well as novel pharmacophoric features. The results of QSAR analysis are further vindicated by reported crystal structures of compounds with factor Xa. The analysis led to the identification of useful novel pharmacophoric features, which could be used for future optimization of lead compounds.


Subject(s)
Fibrinolytic Agents/pharmacology , Heterocyclic Compounds/pharmacology , Thrombosis/drug therapy , Fibrinolytic Agents/chemistry , Heterocyclic Compounds/chemistry , Humans , Models, Molecular , Quantitative Structure-Activity Relationship
7.
Bioorg Chem ; 114: 105076, 2021 09.
Article in English | MEDLINE | ID: covidwho-1262892

ABSTRACT

N-heterocycles are important, not only because of their abundance, but above all because of their chemical, biological and technical significance. They play an important role in biological investigation such as anticancer, antiinflammatory, antibacterial, antiviral, anti-tumor, antidiabetic, etc. In this study, we focused on examining synthesized some 5- or 6-ring N-heterocyclic compounds that showed the antiviral activity in last 5 years, and investigation of these compounds structure-activity relationship studies. This review will be useful to scientists in research fields of organic synthesis, medicinal chemistry, and pharmacology.


Subject(s)
Antiviral Agents/pharmacology , Heterocyclic Compounds/pharmacology , Nitrogen/pharmacology , Viruses/drug effects , Antiviral Agents/chemical synthesis , Antiviral Agents/chemistry , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/chemistry , Humans , Microbial Sensitivity Tests , Nitrogen/chemistry
8.
Molecules ; 26(9)2021 Apr 29.
Article in English | MEDLINE | ID: covidwho-1217103

ABSTRACT

The outbreak of SARS-CoV-2 has drastically changed our everyday life and the life of scientists from all over the world. In the last year, the scientific community has faced this worldwide threat using any tool available in order to find an effective response. The recent formulation, production, and ongoing administration of vaccines represent a starting point in the battle against SARS-CoV-2, but they cannot be the only aid available. In this regard, the use of drugs capable to mitigate and fight the virus is a crucial aspect of the pharmacological strategy. Among the plethora of approved drugs, a consistent element is a heterocyclic framework inside its skeleton. Heterocycles have played a pivotal role for decades in the pharmaceutical industry due to their high bioactivity derived from anticancer, antiviral, and anti-inflammatory capabilities. In this context, the development of new performing and sustainable synthetic strategies to obtain heterocyclic molecules has become a key focus of scientists. In this review, we present the recent trends in metal-promoted heterocyclization, and we focus our attention on the construction of heterocycles associated with the skeleton of drugs targeting SARS-CoV-2 coronavirus.


Subject(s)
Antiviral Agents/pharmacology , COVID-19 Drug Treatment , Chemistry Techniques, Synthetic/methods , Heterocyclic Compounds/pharmacology , SARS-CoV-2/drug effects , Antiviral Agents/chemical synthesis , Antiviral Agents/chemistry , COVID-19/virology , Catalysis , Coronavirus 3C Proteases/antagonists & inhibitors , Coronavirus 3C Proteases/metabolism , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/chemistry , Humans , Metals/chemistry , Protease Inhibitors/chemical synthesis , Protease Inhibitors/chemistry , Protease Inhibitors/pharmacology , SARS-CoV-2/metabolism
9.
Bioorg Chem ; 104: 104315, 2020 11.
Article in English | MEDLINE | ID: covidwho-792999

ABSTRACT

Coronaviruses have led to severe emergencies in the world since the outbreak of SARS CoV in 2002, followed by MERS CoV in 2012. SARS CoV-2, the novel pandemic caused by coronaviruses that began in December 2019 in China has led to a total of 24,066,076 confirmed cases and a death toll of 823,572 as reported by World Health Organisation on 26 August 2020, spreading to 213 countries and territories. However, there are still no vaccines or medications available till date against SARS coronaviruses which is an urgent requirement to control the current pandemic like situations. Since many decades, heterocyclic scaffolds have been explored exhaustively for their anticancer, antimalarial, anti-inflammatory, antitubercular, antimicrobial, antidiabetic, antiviral and many more treatment capabilities. Therefore, through this review, we have tried to emphasize on the anticipated role of heterocyclic scaffolds in the design and discovery of the much-awaited anti-SARS CoV-2 therapy, by exploring the research articles depicting different heterocyclic moieties as targeting SARS, MERS and SARS CoV-2 coronaviruses. The heterocyclic motifs mentioned in the review can serve as crucial resources for the development of SARS coronaviruses treatment strategies.


Subject(s)
Antiviral Agents/pharmacology , COVID-19 Drug Treatment , Heterocyclic Compounds/pharmacology , SARS-CoV-2/drug effects , Severe Acute Respiratory Syndrome/drug therapy , Severe acute respiratory syndrome-related coronavirus/drug effects , Animals , Antiviral Agents/chemistry , Cell Line , Coronavirus Infections/drug therapy , Drug Design , Heterocyclic Compounds/chemistry , Humans , Middle East Respiratory Syndrome Coronavirus/drug effects , Molecular Structure , Pandemics
SELECTION OF CITATIONS
SEARCH DETAIL